A higher risk of adult psychotic experiences is associated with childhood cat ownership.

Published Date: 24 Apr 2023

Canada: The Journal of Psychiatric Research recently reported that childhood cat ownership, particularly with rodent-hunting cats,.

Read Full News

Latest News

Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention

Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

Prenatal Opioid Pain Medications Likely Not Linked to Autism or ADHD Risk Chelsie Derman

A study suggests associations between opioids during pregnancy and neurodevelopmental disorders are mainly due to confounding factors, not causal effects.

Single Dose of MM120 (LSD) Shows Lasting Anxiety Reduction in GAD: Phase 2b Results Chelsie Derman

A phase 2b trial finds a single 100 μg dose of MM120 reduced GAD symptoms with benefits lasting 12 weeks, highlighting the promise of psychedelic therapy.

Todays Updates

Merck’s Novel Antibody MK-2214 Receives FDA Fast-Track Designation Following Phase 1 Results Louie Pasculli

Merck's MK-2214 shows promise in early Alzheimer’s trials, earning FDA fast-track status for its safety and potential efficacy in slowing disease progression.

Dravet Syndrome Medication Stiripentol Effective in Real World Settings Across Various Patient Profiles Marco Meglio

New STIRUS data unveiled at AES 2025 demonstrate meaningful real-world reductions in seizures, status epilepticus, and healthcare needs with stiripentol in Dravet syndrome.

NBI-827104’s Phase 2 Disappointment Highlight Therapeutic Needs for Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep Marco Meglio

New findings reveal the challenges of treating pediatric epileptic encephalopathy with NBI-827104, highlighting the need for effective therapies.

5 FDA Headlines You Missed in November 2025

5 FDA Headlines You Missed in November 2025

Todays Updates

Merck’s Novel Antibody MK-2214 Receives FDA Fast-Track Designation Following Phase 1 Results Louie Pasculli

Merck's MK-2214 shows promise in early Alzheimer’s trials, earning FDA fast-track status for its safety and potential efficacy in slowing disease progression.

Dravet Syndrome Medication Stiripentol Effective in Real World Settings Across Various Patient Profiles Marco Meglio

New STIRUS data unveiled at AES 2025 demonstrate meaningful real-world reductions in seizures, status epilepticus, and healthcare needs with stiripentol in Dravet syndrome.

NBI-827104’s Phase 2 Disappointment Highlight Therapeutic Needs for Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep Marco Meglio

New findings reveal the challenges of treating pediatric epileptic encephalopathy with NBI-827104, highlighting the need for effective therapies.

5 FDA Headlines You Missed in November 2025

5 FDA Headlines You Missed in November 2025

Latest News

Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

A study suggests associations between opioids during pregnancy and neurodevelopmental disorders are mainly due to confounding factors, not causal effects.

A phase 2b trial finds a single 100 μg dose of MM120 reduced GAD symptoms with benefits lasting 12 weeks, highlighting the promise of psychedelic therapy.

News All Time

Digital Therapeutic Reduces Negative Symptoms of Schizophrenia in Phase 3 Trial Chelsie Derman

A new digital therapeutic, CT-155, shows promise in reducing negative symptoms of schizophrenia.

FDA Approves Risperidone Extended-Release Injectable for Bipolar I Disorder Chelsie Derman

FDA approves UZEDY, a long-acting risperidone injection, for adults with bipolar I disorder.

Esmethadone Shows Promise as Adjunctive Treatment for Antidepressant Tolerance Chelsie Derman

Post-hoc analysis of a phase 3 trial reveals significant improvements in patients with MDD experiencing tachyphylaxis.

Magnetic Seizure Therapy Rivals ECT, Protects Cognition in Adolescent MDD Chelsie Derman

A study found magnetic seizure therapy matched ECT’s antidepressant efficacy while offering better cognitive preservation and fewer adverse events.

Antidepressants Differ Significantly in Cardiometabolic Side Effects Chelsie Derman

A large analysis reveals clinically relevant differences in weight, blood pressure, and heart rate across 30 antidepressants.

Repetitive TMS Boosts Quality of Life in Younger, Older Adults with Depression Chelsie Derman

Study finds repetitive transcranial magnetic stimulation brings clinically meaningful improvements in quality of life for adults with MDD through 12 weeks.

Rethinking Addiction Recovery: From Symptoms to Systems

Rethinking Addiction Recovery: From Symptoms to Systems

Comorbid Anxiety Lowers Accelerated Theta Burst Response in Depression Chelsie Derman

A study finds older adults with depression and comorbid anxiety show less improvement after accelerated theta burst stimulation.

Non-Invasive Vagus Nerve Stimulation Boosts Food Liking in Depression Chelsie Derman

Right transcutaneous auricular VNS (taVNS) acutely increases food liking in patients with MDD, especially those with high anhedonia, a study found.

Women Face Higher Risk of Advanced Fibrosis Due to Binge Drinking Than Men

Women Face Higher Risk of Advanced Fibrosis Due to Binge Drinking Than Men

Stigma Around Alcohol-Related Liver Disease Poses Major Barrier to Care

Stigma Around Alcohol-Related Liver Disease Poses Major Barrier to Care

6 Psychiatry Headlines You Missed in October 2025

6 Psychiatry Headlines You Missed in October 2025

Psychedelics might help terminal patients find peace

In clinical trials around the world, a surprising treatment is showing promise for people with terminal illnesses: psychedelic therapy.

Tracing schizophrenia's origins: Study maps chromatin accessibility in postmortem brain tissue

Schizophrenia is a severe neuropsychiatric disorder characterized by hallucinations, false beliefs about oneself or the world (i.e., delusions), and other disruptions in thought, emotion and perception. Recent genetic studies ...

Not all PTSD therapies keep veterans in treatment, study warns

About a quarter of U.S. service members and veterans who start psychotherapy for post-traumatic stress disorder quit before they finish treatment. But not all therapies are equal in their appeal, with some effective approaches ...

Inequalities in mental health compulsory admissions worsened during the pandemic, UK study finds

New research from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) and South London and Maudsley NHS Foundation Trust has shown striking inequalities between ethnic groups in the rate of involuntary admissions ...

Recommended News For You

Having dense breasts is linked to cancer, but advice about breast density can depend on where you live

Hereditary cancer has a rare and underreported cause.

Report suggests a big improvement in lung cancer survival

Algorithm that predicts pancreatic cancer metastasis could help avoid unnecessary surgeries

Modified personalized cancer vaccine generates powerful immune response

The September 2018 issue of Medical Bulletin.

Chemotherapy before surgery helps patients with nose and sinus cancer avoid debilitating eye and bone removal

Recommended Articles For You

Revolutionizing Cancer Treatment with Darzalex: How an Innovative Drug is Transforming Lives 

The Mystery of Carotid Body Tumors: The Facts You Need to Know 

Understanding Blood Dyscrasia: Symptoms, Causes and Treatment Options 

Oncology Drug Trends 2025: FDA Approvals, Immuno-Oncology, and Clinical Trial Insights 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Data-driven risk stratification guides childhood brain tumor treatment, reducing side effects

2.

Early cancer detection during pregnancy and the postpartum period may be aided by breast milk examination.

3.

Five new papers highlight cancer inequities, challenges and opportunities in South Asia

4.

Colorectal Cancer Screening Uptake Tripled in 45-49 Age Group

5.

Report suggests a big improvement in lung cancer survival

1.

Getting to Know RDW and SD: How They Relate to Anemia, Inflammation, and More 

2.

Don't Ignore Your Vision Loss: What You Need to Know About Amaurosis Fugax 

3.

Understanding Fibrosarcoma: What You Need to Know 

4.

Unlocking the Mystery of Leukemia: Exploring New Treatments and Hope for Patients

5.

Gene Signatures and Their Implications in Oncology: Decoding the Blueprint for Personalized Cancer Treatment

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part II

2.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VI

3.

Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option

4.

The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion

5.

Summary of The Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot